Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
Cell Motility and the Cytoskeleton|January 1, 1993
Sarcomeric myosin heavy chain expressed in nonmuscle cells forms thick filaments in the presence of substoichiometric amounts of light chainsK L Vikstrom, A S Rovner, C G Saez, et al.
Plos One|July 18, 2013
Neurogenic detrusor overactivity is associated with decreased expression and function of the large conductance voltage- and Ca(2+)-activated K(+) channelsKiril L Hristov, Serge A Y Afeli, Shankar P Parajuli, et al.
Paediatric Anaesthesia|March 12, 2020
Detection of subclinical Harlequin syndrome in pediatric patientsMichelle S Rovner, Amanda T Redding, Bethany Jacobs Wolf, et al.
Urology|August 30, 2014
Patient perception of transvaginal mesh and the mediaMichelle Elaine Koski, Jennifer Chamberlain, James Rosoff, et al.
International Journal of Impotence Research|September 26, 2000
Erectile function and quality of life after interstitial radiation therapy for prostate cancerR F Sánchez-Ortiz, G A Broderick, E S Rovner, et al.
The Journal of Urology|December 22, 1999
Artificial urinary sphincter for post-prostatectomy incontinence: impact of prior collagen injection on cost and clinical outcomeC M Gomes, G A Broderick, R F Sánchez-Ortiz, et al.
The American Journal of Physiology|March 11, 1989
Reciprocal changes of muscle oxidases and liver enzymes with recovery from iron deficiencyJ L Azevedo, W T Willis, L P Turcotte, et al.
Advances in Therapy|June 22, 2019
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)Kevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
Lower Urinary Tract Symptoms|May 14, 2021
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry studyKevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
BJU International|August 17, 2010
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndromePeter K Sand, Theodore M Johnson Ii, Eric S Rovner, et al.
Pageof 16